secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2023-09-25T23:59:59+00:00
Accession:  0001493152-23-033590
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharmaceuticals files ANDA for generic opiate analgesic with $720M market
-------------------------------------------------------------------------------

- Filed ANDA with FDA on August 17, 2023 for a generic opiate analgesic product.
- FDA accepted the ANDA for review on September 19, 2023.
- IQVIA reported $720 million in annual brand and generic sales for this product (12 months ending June 2023).
- The specific drug product remains undisclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315223033590/0001493152-23-033590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315223033590/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-033590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer